INmune Bio Teams Up to Advance CORDStrom™ Production
INmune Bio Inc. (NASDAQ: INMB), a pioneering name in biotechnology, has forged an essential partnership with the Cell and Gene Therapy Catapult (CGT Catapult) to enhance CORDStrom™ production capabilities for commercial readiness. With a firm commitment to addressing critical inflammatory and immunological conditions through innate immune system advancements, INmune Bio is poised to revolutionize treatments for several severe diseases.
What is CORDStrom™?
CORDStrom™ is a cutting-edge therapy aimed at patients suffering from recessive dystrophic epidermolysis bullosa (RDEB), a challenging genetic skin disorder. A recent Phase 2 randomized trial highlighted the therapy's encouraging potential in reducing pain, itch, and improving overall skin health for patients afflicted with RDEB. This partnership with CGT Catapult signifies a major step toward realizing CORDStrom™'s potential to become a cornerstone in the treatment landscape for RDEB, with an estimated 4,000 children in need of effective treatments across major global markets.
Collaboration with CGT Catapult
The collaboration leverages the advanced expertise of CGT Catapult, an organization dedicated to evolving the field of cell and gene therapy. Their state-of-the-art manufacturing facility at the Stevenage Manufacturing Innovation Centre provides a robust backbone for scaling up the production of CORDStrom™. This strategic partnership not only accelerates INmune Bio's commercialization trajectory but also assures operational control throughout the production process.
Quotes from Key Leaders
Matthew Durdy, Chief Executive of CGT Catapult, emphasized the significance of this collaboration in addressing pressing healthcare challenges and the benefits it will bring to the UK community by ensuring patients have access to innovative therapies. He stated, "We are delighted to support INmune Bio’s journey to commercialize their therapies while contributing to the advancement of global health care standards."
Future Directions for INmune Bio
After successfully scaling CORDStrom™, INmune Bio aims to shift the production of INKmune®, their promising NK-priming cell therapy, to the same Stevenage facility. This will not only enhance their operational efficiency but also streamline ongoing trials for various cancer indications, including metastatic castration-resistant prostate cancer.
Significance of the Collaboration
Professor Mark Lowdell, Chief Scientific Officer of INmune Bio, described the partnership as an excellent example of cross-border collaboration in the scientific community. This collaboration builds a strong foundation for continuing to innovate and develop new treatments that have the potential to change patient lives significantly.
Understanding INmune Bio's Broader Impact
INmune Bio is dedicated to developing therapies targeted at the innate immune system, focusing on diseases that have severe unmet medical needs. Their strategic partnerships and advancements in technology reflect their commitment not just to patients but also to the broader biotech industry. With products like CORDStrom™ and INKmune®, they are well-positioned to play a vital role in the evolution of personalized medicine and targeted therapeutic interventions.
Explore the Damage from Innate Immune Dysfunction
Their innovative approaches also include utilizing dominant-negative technology to tackle challenges like the generation of pro-inflammatory cytokines, key players in many chronic diseases. As they proceed through clinical trials, their potential to reshape therapeutic protocols continues to grow, offering hope to many who face significant health struggles.
Frequently Asked Questions
What is CORDStrom™?
CORDStrom™ is a cell therapy aimed at treating recessive dystrophic epidermolysis bullosa (RDEB), targeting the symptoms associated with this genetic skin disorder.
What role does CGT Catapult play in this partnership?
CGT Catapult provides expertise and infrastructure for large-scale manufacturing, essential to bring CORDStrom™ and future therapies to the market efficiently.
What are other therapies being developed by INmune Bio?
Other than CORDStrom™, INmune Bio is also advancing INKmune®, focused on enhancing the body's immune response to fight solid tumors.
How does INmune Bio plan to address market needs?
INmune Bio’s strategic partnerships and innovative therapies aim to satisfy significant unmet medical needs within the realm of inflammatory and immunological disorders.
What is the future outlook for INmune Bio?
With active trials and collaborations, INmune Bio is set to expand its therapeutic offerings, focusing on the commercial viability of its innovative treatments while continuing its commitment to patient care.
